Clinical Trial Detail

NCT ID NCT01396408
Title A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors NCIC Clinical Trials Group
Indications

fibrolamellar carcinoma

adrenal medulla cancer

hemangiopericytoma

angiosarcoma

ovarian clear cell adenocarcinoma

Ewing sarcoma

endometrial clear cell adenocarcinoma

adrenal cortex cancer

thymic carcinoma

thyroid gland medullary carcinoma

paraganglioma

Therapies

Temsirolimus

Sunitinib

Age Groups: senior adult

Additional content available in CKB BOOST